Is the Oral Wegovy Pill the Best Semaglutide Option for 2026?
On December 22, 2025, Novo Nordisk announced that the U.S. Food and Drug Administration approved its 25 mg oral Wegovy weight-loss pill—the first FDA-approved oral GLP-1 therapy for chronic weight management in adults. The decision was also reported by independent outlets including ABC News. (Rybelsus, an earlier oral semaglutide product, is approved for type 2 diabetes but not for weight management.) According to the company’s announcement, Novo Nordisk plans a full U.S. launch in early January 2026; availability may vary.
According to independent news reporting, the oral Wegovy pill demonstrated meaningful average weight loss in the OASIS 4 trial and is expected to launch in early January 2026.
This regulatory milestone arrives as consumer search interest for weight loss medications often increases around the New Year period. For individuals researching “best semaglutide,” the FDA decision reshapes the comparison landscape by adding an FDA-approved oral pathway alongside existing injectable and compounded options.
Excerpted from BioSpace
